Table 4 |
||||||
|
Detection of antibodies against γ2bTCR-I in vaccinated Lewis rats |
||||||
|
Days After Vaccination |
||||||
|
|
||||||
|
Immunogen |
Rats (No.) |
Responders (No.) |
0 |
21 |
28 |
50 |
|
|
||||||
|
γ2bTCR-I |
6 |
6/6 |
≤2.3 |
3.2 ± 0,2 |
3.7 ± 0.1 |
4 ± 0.3 |
|
γ2bWT |
6 |
6/6 |
≤2.3 |
3 ± 0.3 |
3.4 ± 0.3 |
3.6 ± 0.3 |
|
CFA |
2 |
0/2 |
≤2.3 |
≤2.3 |
≤2.3 |
≤2.3 |
|
- |
3 |
0/3 |
- |
- |
≤2.3 |
≤2.3 |
|
|
||||||
|
* Antibody titers are expressed in log10. Sera were tested on microtiter plates coated with γ2bTCR-I. End point dilutions were determined as the last serum dilution binding with an OD ≥ 0.200. |
||||||
|
Musselli et al. Journal of Immune Based Therapies and Vaccines 2004 2:9 doi:10.1186/1476-8518-2-9 |
||||||
